NCT05704478Active, not recruitingPhase 4
Impact of Vericiguat on Hemodynamics of Heart Failure
Impact of Vericiguat on Vascular Biology, as Well as Resting and Exertional Cardiovascular Performance Among Patients With Heart Failure With Reduced Ejection Fraction
Source: ClinicalTrials.gov · Last updated 13 Nov 2025
Brief summary (registry, in English)
Vericiguat is a new drug that was recently approved by the Food and Drug Administration for patients with heart failure. In a large randomized controlled trial, this drug was found to help patients with heart failure live longer and stay out of the hospital more than normal treatment for heart failure. However, it is unclear how this drug positively impacts "hemodynamics", meaning how the heart functions during activity/exercise, and how it may also help blood pressure and health of the blood vessels and autonomic nervous system. This study, funded by the drug manufacturer, Merck Corp, will enroll 30 patients with heart failure. The patients will undergo baseline testing, and then be randomized to either receive vericiguat or a placebo for about three months, and then come back for follow-up testing to learn more about how the drug impacts heart function.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 11 Jan 2023
- Start date
- 1 Jan 2024
- Primary completion date
- 31 Mar 2026
- Lead sponsor
- University of Colorado, Denver
- Diseases
- Heart failure
- NCT number
- NCT05704478
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 30
- From 1 Jan 2024 to the primary completion date, 31 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- use of long-acting nitrates, soluble guanylate cyclase stimulators, or phosphodiesterase type 5 inhibitors;
- use of anticoagulants with an inability to temporarily hold these medications for procedures or to keep the international normalized ratio \< 2.5 units;
Other illness
- uncontrolled arrhythmias;
- noncardiac factors that may limit the ability to exercise (e.g. severe osteoarthritis, peripheral vascular disease, severe pulmonary disease); and
Other
- systolic blood pressure (SBP) below 100mmHg;
- use of intravenous inotropes or implantable left ventricular assist devices;
- pregnancy.
Who the study is looking for
- Adults 18 years of age or greater with New York Heart Association functional class II, III, or IV HFrEF with left ventricular ejection fraction \< 45% within 12 months of enrollment;
- elevated brain natriuretic peptide level (BNP) within 30 days of enrollment; and
- history of worsening congestion, defined as a HF-hospitalization within 6 months of enrollment or increase in diuretic therapy without hospitalization within three months of enrollment.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Colorado Anschutz Medical Campus Coordinator of this site? Confirm its status | Aurora | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.